Marfan's syndrome cost-effectiveness of therapy
Editors-In-Chief: William James Gibson, C. Michael Gibson, M.S., M.D.
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [1] ; Assistant Editor-In-Chief: Cassandra Abueg, M.P.H. [2]
Overview
Overview
Cost Effectiveness
Cost Effectiveness
Currently, laboratories offer complete sequencing of the 65 exon FBN1 gene for approximately $1700.00 [1]. The high costs of these diagnostics have delayed the widespread use of molecular diagnostics in the approach to patients suspected of Marfan syndrome. Increasingly less expensive sequencing technologies promise to increase reliance on individual genetic data for diagnosis in the future.
References
References
- ↑ (Accessed November 22, 2010, at http://www.bcm.edu/pediatrics/index.cfm?Realm=99992426&This_Template=FBN1.)
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH